{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:21:17Z","timestamp":1792693277723,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>Multiple sclerosis (MS)-related inflammation can be divided into lesional activity, mediated by immune cells migrating from the periphery to the central nervous system (CNS) and non-lesional activity, mediated by inflammation compartmentalized to CNS tissue. Lesional inflammatory activity, reflected by contrast-enhancing lesions (CELs) on the magnetic resonance imaging (MRI), is effectively inhibited by current disease modifying therapies (DMTs). While, the effect of DMTs on non-lesional inflammatory activity is currently unknown. Reliable and simultaneous measurements of both lesional and non-lesional MS activity is necessary to understand their contribution to CNS tissue destruction in individual patients. We previously demonstrated that CNS compartmentalized inflammation can be measured by combined quantification of cerebrospinal fluid (CSF) immune cells and cell-specific soluble markers. The goal of this study is to develop and validate a CSF-biomarker-based molecular surrogate of MS lesional activity. The training cohort was dichotomized into active (CELs &amp;gt; 1 or clinical relapse) and inactive lesional activity (no CELs or relapse) groups. Matched CSF and serum samples were analyzed for 20 inflammatory and axonal damage biomarkers in a blinded fashion. Only the findings from the training cohort with less than 0.1% probability of false positive (i.e.,<jats:italic>p<\/jats:italic>&amp;lt; 0.001) were validated in an independent validation cohort. MS patients with lesional activity have elevated IL-12p40, CHI3L1, TNF\u03b1, TNF\u03b2, and IL-10, with the first two having the strongest effects and validated statistically-significant association with lesional activity in an independent validation cohort. Marker of axonal damage, neurofilament light (NfL), measured in CSF (cNfL) was also significantly elevated in MS patients with active lesions. NfL measured in serum (sNfL) did not differentiate the two MS subgroups with pre-determined significance, (<jats:italic>p<\/jats:italic>= 0.0690) even though cCSF and sNfL correlated (Rho = 0.66,<jats:italic>p<\/jats:italic>&amp;lt; 0.0001). Finally, the additive model of IL12p40 and CHI3L1 outperforms any biomarker discretely. IL12p40 and CHI3L1, released predominantly by immune cells of myeloid lineage are reproducibly the best CSF biomarkers of MS lesional activity. The residuals from the IL12p40\/CHI3L1-cNfL correlations may identify MS patients with more destructive inflammation or contributing neurodegeneration.<\/jats:p>","DOI":"10.3389\/fnins.2021.649876","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T05:04:57Z","timestamp":1617080697000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity"],"prefix":"10.3389","volume":"15","author":[{"given":"Ruturaj","family":"Masvekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibiana","family":"Bielekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12035-019-01698-3","article-title":"Neurofilament light chain as a biomarker, and correlation with magnetic resonance imaging in diagnosis of CNS-Related disorders.","volume":"57","author":"Alirezaei","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ana.22054","article-title":"Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords.","volume":"68","author":"Androdias","year":"2010","journal-title":"Ann. Neurol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.18.20105932","article-title":"Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms.","author":"Barbour","year":"2020","journal-title":"medRxiv"},{"key":"B4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ana.20016","article-title":"Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion.","volume":"55","author":"Barnett","year":"2004","journal-title":"Ann. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/80516","article-title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.","volume":"6","author":"Bielekova","year":"2000","journal-title":"Nat. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.msard.2018.05.017","article-title":"Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes.","volume":"24","author":"Boesen","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-7-34","article-title":"In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases.","volume":"7","author":"Bonneh-Barkay","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study.","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/brain\/awv017","article-title":"Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.","volume":"138","author":"Canto","year":"2015","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/brain\/awq035","article-title":"Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.","volume":"133","author":"Comabella","year":"2010","journal-title":"Brain"},{"key":"B11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.it.2006.11.002","article-title":"IL-12p40: an inherently agonistic cytokine.","volume":"28","author":"Cooper","year":"2007","journal-title":"Trends Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis.","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1474-4422(18)30451-4","article-title":"Association between pathological and MRI findings in multiple sclerosis.","volume":"18","author":"Filippi","year":"2019","journal-title":"Lancet Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains.","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"key":"B15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1126\/science.279.5350.514","article-title":"A structural scaffolding of intermediate filaments in health and disease.","volume":"279","author":"Fuchs","year":"1998","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders.","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ana.21800","article-title":"Multiple sclerosis: distribution of inflammatory cells in newly forming lesions.","volume":"66","author":"Henderson","year":"2009","journal-title":"Ann. Neurol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/413465","article-title":"Initial immunopathogenesis of multiple sclerosis: innate immune response.","volume":"2013","author":"Hern\u00e1ndez-Pedro","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1097\/NEN.0b013e3181f3a5b1","article-title":"Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis.","volume":"69","author":"Howell","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1039\/c2lc20744c","article-title":"Isolation and detection of single molecules on paramagnetic beads using sequential fluid flows in microfabricated polymer array assemblies.","volume":"12","author":"Kan","year":"2012","journal-title":"Lab Chip"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.4049\/jimmunol.156.3.1110","article-title":"Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression. implications in immunopathogenesis and protection.","volume":"156","author":"Kanangat","year":"1996","journal-title":"J. Immunol."},{"key":"B22","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.4049\/jimmunol.157.7.2851","article-title":"IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease. possible involvement of IFN-gamma.","volume":"157","author":"Kichian","year":"1996","journal-title":"J. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ana.24408","article-title":"Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.","volume":"78","author":"Komori","year":"2015","journal-title":"Ann. Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.msard.2015.08.009","article-title":"Novel composite MRI scale correlates highly with disability in multiple sclerosis patients.","volume":"4","author":"Kosa","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult. Scler."},{"key":"B26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","article-title":"Serum neurofilament is associated with progression of brain atrophy and disability in early MS.","volume":"88","author":"Kuhle","year":"2017","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology.","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3<3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01241","article-title":"Quantifications of CSF apoptotic bodies do not provide clinical value in multiple sclerosis.","volume":"10","author":"Masvekar","year":"2019","journal-title":"Front. Neurol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64093-2","article-title":"Chitinase 3-like 1 is neurotoxic in primary cultured neurons.","volume":"10","author":"Matute-Blanch","year":"2020","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01232","article-title":"Intrathecal, not systemic inflammation is correlated with multiple sclerosis severity, especially in progressive multiple sclerosis.","volume":"10","author":"Milstein","year":"2019","journal-title":"Front. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrneurol.2016.110","article-title":"Myeloid cells-targets of medication in multiple sclerosis.","volume":"12","author":"Mishra","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419840593","article-title":"Advances in spinal cord imaging in multiple sclerosis.","volume":"12","author":"Moccia","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.14670\/HH-11-699","article-title":"Myeloid cell distribution and activity in multiple sclerosis.","volume":"31","author":"Molin\u00e9-Vel\u00e1zquez","year":"2016","journal-title":"Histol. Histopathol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","article-title":"Neurofilament and glial fibrillary acidic protein in multiple sclerosis.","volume":"63","author":"Norgren","year":"2004","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.1255","article-title":"Immunopathology of secondary-progressive multiple sclerosis.","volume":"50","author":"Prineas","year":"2001","journal-title":"Ann. Neurol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations.","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ana.24052","article-title":"Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.","volume":"75","author":"Scherling","year":"2014","journal-title":"Ann. Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458518765666","article-title":"Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.","volume":"25","author":"Siller","year":"2019","journal-title":"Mult. Scler. J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(13)70103-0","article-title":"MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.","volume":"12","author":"Sormani","year":"2013","journal-title":"Lancet Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1177\/1352458512443092","article-title":"Neurofilaments as biomarkers in multiple sclerosis.","volume":"18","author":"Teunissen","year":"2012","journal-title":"Mult. Scler."},{"key":"B44","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135886","article-title":"Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction.","volume":"10","author":"V\u00e5gberg","year":"2015","journal-title":"PLoS One"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2021.649876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T10:23:22Z","timestamp":1698143002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2021.649876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":45,"alternative-id":["10.3389\/fnins.2021.649876"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2021.649876","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"article-number":"649876"}}